Microbead-Free Waters Act of 2014

H.R. 322, Hunting, Fishing and Recreational Shooting Protection Act (Toxic Substances Control Act Provisions); H.R. 527, Helium Stewardship Act of 2013; H.R. 888, General Duty Clarification Act of 2013; H.R. 1287, Sound Science Act of 2013; H.R. 2248, Ban Poisonous Additives Act of 2013, H.R. 1422, EPA Science Advisory Board Reform Act of 2013; H.R. 4012, Secret Science Reform Act of 2014; H.R. 4159, America Competes Reauthorization Act of 2014 (Nanotechnology Provisions); H.R. 4795, Promoting New Manufacturing Act; H.R. 4895, Microbead-Free Waters Act of 2014; H.R. 5033, Ban Poisonous Additives Act of 2014; S. 696, Safe Chemicals Act of 2013; S. 783, Helium Stewardship Act of 2013; S. 814, Protecting Communities from Chemical Explosions Act of 2013; S. 1009, Chemical Safety Improvement Act; S. 1124, BPA in Food Packaging Right to Know Act; S. 1468, Revitalize American Manufacturing and Innovation Act of 2013; S. 1781, General Duty Clarification Act of 2013; S. 1853, EPA Science Advisory Board Reform Act of 2013; S. 1961, Chemical Safety and Drinking Water Protection Act of 2014; S. 2006, National Rare Earth Cooperative Act of 2014; S. 2120, A bill to regulate children's products that contain phthalates; S. 2363, Bipartisan Sportsmen's Act of 2014; S. 2572, Ban Poisonous Additives Act of 2014; S. 2613, Secret Science Reform Act of 2014; S. 2656, Protecting America's Families from Toxic Chemicals Act of 2014; S. 2811, Children and Firefighters Protection Act of 2014; S. 2833, CASE Act; S. 2879, Sustainable Chemistry Research and Development Act of 2014; S. 2902, Microbead Free Waters Act of 2014; Appropriations for Commerce, Justice, Science FY 2015; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations FY 2015 (National Toxicology Program within HHS, Report on Carcinogens); Financial Services and General Government Appropriations Act, 2015 (GSA and Green Building Policies, Phthalates, CHAP and CPSC); Interior Appropriations FY 2015 (EPA Funding); Toxic Substances Control Act (TSCA) Modernization and Reform; Chemicals in Commerce Act (House Discussion Draft); TSCA Inventory Update Rule; T-TIP, MTB and Trade Promotion Authority; Access to Federally Funded Research Data; Chemical Safety Board; Confidential Business Information Disclosures under TSCA; Design for the Environment; EPA's Integrated Risk Information System (including Assessments on Dioxin, Formaldehyde and Hexavalent Chromium) and Good Science; EPA Science Advisory Board Reform; Asbestos; Bisphenol A; CPSC Phthalates CHAP; Crystalline Silica; EPEAT Environmental Assessment Tool; Flame Retardants; Formaldehyde; Helium; Hexavalent Chromium; Mercury; Nanotechnology; Polystyrene foodservice; Rare Earths; Styrene; Federal Government Use of Green Building Standards, Including "LEED"; Improving Federal Agency Chemical Risk Assessments; Regulatory Reform; Vinyl Industry Related Issues

Client expense: $3,200,000 · Firm income: Not reported

Government targets: Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Office of Management & Budget (OMB), SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of

Dextromethorphan Abuse Reduction; Regulation of OTC drugs, devices and cosmetics; S.644, Preventing Abuse of Cough Treatments Act of 2013; HR 3969, Preventing Abuse of Cough Treatments Act of 2013; S.2141, The Sunscreen Innovation Act; HR 4250, The Sunscreen Innovation Act; HR 4895/S.2902, Microbead-Free Waters Act of 2014; HR 5613, Protecting Our Kids' Medicine Act of 2014

Client expense: $1,060,676 · Firm income: Not reported

Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to Physician Payment Sunshine provisions. - Issues related to regulation and reimbursement of diagnostics.- Issues related to health care reform, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 1074, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 539, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 452, "Medicare Diabetes Prevention Act of 2013", regarding all provisions. - Issues related to personalized medicine incentives and regulation. - Issues related to Moddern Cures initiative. - Issues related to modernizing laboratory test standards. - Issues related to diagnostic payments. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to vision care coverage. - PL 112-144, "Food and Drug Administration Safety and Innovation Act", regarding Medical Device User Fee Act provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - Issues related to hepatitis C testing and treatment guidelines. - PL 101-381, "Ryan White Comprehensive AIDS Resources Emergency (CARE) Act" and issues related to state ADAP funding. - Issues related to drug resistant tuberculosis. - Issues related to legislation that would establish drug importation. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to medical device reprocessing. - Issues related to health care pricing transparency. - HR 3303, "Mobile Medical Application", regarding all provisions. - Issues related to health care associated inflation policy. - HR 2663/ S 1422, "Preventative Health Savings Act", regarding all provisions. - HR 3204, "Drug Quality and Security Act", regarding all provisions. - Issues related to neglected tropical diseases. - Issues related to transferable market exclusivity. - Issues related to health care associated infections. - S 959, "Pharmaceutical Quality Security and Accountability Act", regarding all provisions. - Issues related to FDA regulation of custom medical devices. - Issues related to Tricare coverage of Total Disc Arthroplasty. - Issues related to VA requirements for vendor access and credentialing. - Issues related to 21st Century Cures. - Issues related to Medicare beneficiary access. - Issues related to mobile medical applications and digital healthcare. - Issues related to FDA draft guidances on blood glucose meters. - HR 4895/ S 2902, "The Microbead Free Waters Act of 2014", regarding all provisions. - Issues related to the expanded use of unapproved drugs. - Issues related to combination products. - Issues related to the PROTECT Act (bill number pending), specifically medical mobile applications. - Issues related to Government Health Care Exclusion/ Debarment (bill number pending)

Dextromethorphan Abuse Reduction; Regulation of OTC drugs, devices and cosmetics; S.644, Preventing Abuse of Cough Treatments Act of 2013; HR 3969, Preventing Abuse of Cough Treatments Act of 2013; S.2141, The Sunscreen Innovation Act; HR 4250, The Sunscreen Innovation Act; HR 4895, Microbead-Free Waters Act of 2014

Client expense: $1,571,606 · Firm income: Not reported

Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

- Issues related to ensuring quality of supply chain for FDA regulated products. - Issues related to Accountable Care Organizations. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to Physician Payment Sunshine provisions. - Issues related to regulation and reimbursement of diagnostics.- Issues related to health care reform, regarding Medicare wellness benefit. - Issues related to maintaining the biosimilars statute without changes. - HR 1074, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 539, "National Diabetes Clinical Care Commission Act", regarding all provisions. - S 452, "Medicare Diabetes Prevention Act of 2013", regarding all provisions. - Issues related to personalized medicine incentives and regulation. - Issues related to Moddern Cures initiative. - Issues related to modernizing laboratory test standards. - Issues related to diagnostic payments. - PL 111-148, "Patient Protection and Affordable Care Act", issues related to vision care coverage. - PL 112-144, "Food and Drug Administration Safety and Innovation Act", regarding Medical Device User Fee Act provisions. - Issues related to the repeal and/or reform of Independent Payment Advisory Boards. - Issues related to hepatitis C testing and treatment guidelines. - PL 101-381, "Ryan White Comprehensive AIDS Resources Emergency (CARE) Act" and issues related to state ADAP funding. - Issues related to drug resistant tuberculosis. - Issues related to legislation that would establish drug importation. - Issues related to legislation that would establish a rebate in the Medicare Part D program. - Issues related to legislation that would modify the Medicare Part B drug reimbursement program. - Issues related to medical device reprocessing. - Issues related to health care pricing transparency. - HR 3303, "Mobile Medical Application", regarding all provisions. - HR 2085, "Diagnostic Payment Reform", regarding all provisions. - Issues related to health care associated inflation policy. - HR 2663/ S 1422, "Preventative Health Savings Act", regarding all provisions. - HR 3204, "Drug Quality and Security Act", regarding all provisions. - Issues related to neglected tropical diseases. - Issues related to transferable market exclusivity. - HR 4015, "SGR Repeal and Medicare Provider Payment Modernization Act of 2014", regarding all provisions. - Issues related to health care associated infections. - S 959, "Pharmaceutical Quality Security and Accountability Act", regarding all provisions. - Issues related to FDA regulation of custom medical devices. - Issues related to Tricare coverage of Total Disc Arthroplasty. - Issues related to VA requirements for vendor access and credentialing. - Issues related to 21st Century Cures. - Issues related to Medicare beneficiary access. - Issues related to mobile medical applications and digital healthcare. - Issues related to FDA draft guidances on blood glucose meters. - HR 4895, "The Microbead Free Waters Act of 2014", regarding all provisions. - Issues related to the expanded use of unapproved drugs.

H.R. 322, Hunting, Fishing and Recreational Shooting Protection Act (Toxic Substances Control Act Provisions); H.R. 527, Helium Stewardship Act of 2013; H.R. 888, General Duty Clarification Act of 2013; H.R. 1287, Sound Science Act of 2013;H.R. 1422, EPA Science Advisory Board Reform Act of 2013; H.R. 4012, Secret Science Reform Act of 2014; H.R. 4159, America Competes Reauthorization Act of 2014 (Nanotechnology Provisions); H.R. 4795, Promoting New Manufacturing Act; H.R. 4895, Microbead-Free Waters Act of 2014; H.R. 5033, Ban Poisonous Additives Act of 2014; S. 696, Safe Chemicals Act of 2013; S. 783, Helium Stewardship Act of 2013; S. 814, Protecting Communities from Chemical Explosions Act of 2013; S. 1009, Chemical Safety Improvement Act; S. 1468, Revitalize American Manufacturing and Innovation Act of 2013; S. 1781, General Duty Clarification Act of 2013; S. 1853, EPA Science Advisory Board Reform Act of 2013; S. 1961, Chemical Safety and Drinking Water Protection Act of 2014; S. 2006, National Rare Earth Cooperative Act of 2014; S. 2120, A bill to regulate children's products that contain phthalates; S. 2363, Bipartisan Sportsmen's Act of 2014; S. 2572, Ban Poisonous Additives Act of 2014; Appropriations for Commerce, Justice, Science FY 2015; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations FY 2015 (National Toxicology Program within HHS, Report on Carcinogens); Financial Services and General Government Appropriations Act, 2015 (GSA and Green Building Policies, Phthalates CHAP and CPSC); Interior Appropriations FY 2015 (EPA Funding); Toxic Substances Control Act (TSCA) Modernization and Reform; Chemicals in Commerce Act (House Discussion Draft); TSCA Inventory Update Rule; T-TIP, MTB and Trade Promotion Authority; Access to Federally Funded Research Data; Chemical Safety Board; Confidential Business Information Disclosures under TSCA; Design for the Environment; EPA's Integrated Risk Information System (including Assessments on Dioxin, Formaldehyde and Hexavalent Chromium) and Good Science; EPA Science Advisory Board Reform; Asbestos; Bisphenol A; CPSC Phthalates CHAP; Crystalline Silica; EPEAT Environmental Assessment Tool; Flame Retardants; Formaldehyde; Helium; Hexavalent Chromium; Mercury; Nanotechnology; Rare Earths; Styrene; Federal Government Use of Green Building Standards, Including "LEED"; Improving Federal Agency Chemical Risk Assessments; Regulatory Reform; Vinyl Industry Related Issues